TABLE 1.
Variables | Total sample (n=411) | First Nations or Métis (n=257, 70.8%) | Others* (n=106, 29.2%) |
---|---|---|---|
Follow-up time, months, median (IQR) | 27.6 (31.9) | 27.6 (29.9) | 32.6 (37.7) |
Variable at baseline | |||
Age at enrollment, years, mean ± SD | 35.7±10.3 | 33.7±9.1 | 41±11.5 |
Exposure category† | |||
MSM | 21 (6.5) | 1(0.5) | 20 (22.0) |
MSM/IDU | 12 (3.7) | 5 (2.3) | 6 (6.6) |
IDU | 244 (75.5) | 193 (89.8) | 36 (39.5) |
Heterosexual contact | 46 (14.2) | 16 (7.4) | 29 (31.9) |
Site | |||
PLP | 188 (45.7) | 100 (38.9) | 80 (75.5) |
WSCC | 122 (29.7) | 84 (32.7) | 7 (6.6) |
Both | 101 (24.6) | 73 (28.4) | 19 (17.9) |
CD4+ count, cells/µL | |||
n, mean ± SD | 300, 379±233 | 181, 369±218 | 87, 376±236 |
Missing, n | 111 | 76 | 19 |
CD4+ count, cells/µL | |||
<200 | 68 (22.7) | 39 (21.6) | 21 (24.1) |
200–350 | 88 (29.3) | 60 (33.1) | 22 (25.3) |
>350 | 144 (48.0) | 82 (45.3) | 44 (50.6) |
Log10 of viral load, copies/mL | |||
n, mean ± SD | 276, 4.3±1.0 | 167, 4.2±1.0 | 85, 4.4±1.0 |
Missing, n | 135 | 90 | 21 |
HCV antibody positive | 312 (80.2) | 227 (92.6) | 47 (46.5) |
Missing, n | 22 | 12 | 5 |
History of IDU | 300 (73.3) | 222 (87.1) | 43 (40.6) |
Missing, n | 2 | 2 | |
STI | 134 (32.6) | 86 (33.5) | 38 (35.8) |
Time-dependent variables | |||
Incarcerated during follow-up | 118 (28.7) | 89 (34.6) | 22 (20.7) |
Ever use of social assistance | 146 (35.5) | 110 (42.8) | 25 (23.6) |
Ever use of ART | 257 (62.5) | 167 (65.0) | 70 (66.0) |
ART naïve | 154 (37.5) | 90 (35.0) | 36 (34.0) |
Case management | 54 (13.1) | 45 (17.5) | 4 (3.8) |
Clinical AIDS | 30 (7.3) | 18 (7.0) | 12 (11.3) |
All-cause mortality | 29 (7.1) | 20 (7.8) | 8 (7.5) |
Data presented as n (%) unless otherwise indicated.
48 were missing;
88 were missing. ART Antiretroviral therapy; HCV Hepatitis C virus, IDU Injection drug use; IQR Interquartile range; MSM Men who have sex with men; PLP Positive Living Program; STI Sexually transmitted infection; WSCC Westside Community Clinic